Diabetes Medicine May Help Prevent Colorectal Cancer: Study

Colorectal Cancer

A new study report was published on December 7 in the journal JAMA Oncology, which suggests that certain types of diabetes medicines may lower the risk for colorectal cancer.

This experiment was conducted by researchers from Case Western Reserve School of Medicine in Cleveland. 

According to Rong Xu, this is the first indication that a certain class of drugs that are used to treat diabetes and obesity can reduce the risk of colorectal cancer.  Rong Xu is the co-lead author of this study and a professor at Case Western’s School of Medicine.

Researchers compared different types of drugs that are used to treat diabetes and obesity and found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more efficient than other anti-diabetic drugs in lowering the risk for colorectal cancer (CRC).

What The Research And Studies Says?

The findings of this study show the possibility that GLP-1 RAs can reduce the risk of colorectal cancer, and therefore, clinical trials are required to get a better understanding of the effectiveness of these drugs.

Nathan Berger said that the reports of this study clearly indicate that GLP-1 RAs are more efficient in preventing colorectal cancer than other anti-diabetic medicines like Metformin and insulin.

Nathan Berger is the co-lead author of this study and Hanna-Payne professor of experimental medicine at Case Western Reserve School of Medicine in Cleveland.

GLP-1 RAs like Ozempic are very popular to treat type 2 diabetes and obesity, and now this study found that they can also reduce the risk of colorectal cancer. There is already a huge demand for these drugs, and from time to time, it has been seen that these drugs run out of the market.

Now, if these drugs show the same results of lowering the risk of colorectal cancer in clinical trials, then the demand for GLP-1 RAs will increase.

The companies that make these drugs will surely face challenges in fulfilling the demands for GLP-1 RAs. The cases of fake Ozempic medicines have been found in many countries, including the United States of America.

The huge demand for these drugs allows criminals to play with other people’s lives by providing them with fake medicines. In such cases, people have to be aware of the original drugs, as fake drugs may cause them more problems.

Research And Studies About Colorectal Cancer

How Did The Researchers Conclude That GLP-1 RAs Can Reduce The Risk Of Colorectal Cancer?

The researchers used the health records of more than 100 million people from a national database who were treated with different anti-diabetic medicines. The researchers used data from more than 1 million patients who were treated between 2005 to 2019 with anti-diabetic medicines.

Further, researchers compared the risk of colorectal cancer in people who were treated with GLP-1 RAs with those who were treated with other anti-diabetic medicines.

The results were shocking because people who were treated with GLP-1 RAs are at 44% lower risk of having colorectal cancer as compared to those who were treated with other drugs.

For example, from the health records of more than 22 thousand patients who were treated with insulin, 167 had to deal with colorectal cancer.

Also, researchers analyzed the same number of patients who were treated with GLP-1 RAs, and they found that 94 people had to deal with colorectal cancer.

Similarly, researchers also analyzed the health records of more than 18 thousand patients who were treated with metformin. The researchers found that there was a 25% lower risk of colorectal cancer in those who were treated with GLP-1 RAs.

This clearly shows that GLP-1 RAs are working and efficient in preventing colorectal cancer. According to Nathan Berger, this experiment will be beneficial for preventing colorectal cancer in all types of people.

Since these drugs are used for treating diabetes and obesity, people may think that GLP-1 RAs will only work for patients with overweight. However, GLP-1 RAs will reduce the risk of colorectal cancer in patients who are overweight and also in those people who have normal weight, according to Nathan Berger.

According to the American Cancer Society, colorectal cancer is the third-leading type of cancer and the second-leading cause of cancer mortality.

Therefore, it is very important to prevent colorectal cancer, and according to this new study, GLP-1 RAs can be beneficial in preventing colorectal cancer.

Also Read: Breast Cancer May Develop As A Result Of Early-Life Gene Epimutations

Leave a Comment